<![CDATA[Trastuzumab Botidotin Prolongs PFS vs T-DM1 in HER2+ Advanced Breast Cancer]]>
Phase 3positiveTrastuzumab botidotinTrastuzumab emtansinePositive
AI Analysis
Summary
Trastuzumab botidotin demonstrated superior efficacy to T-DM1 in the Phase 3 KL166-III-06 trial for HER2-positive advanced breast cancer, more than doubling median progression-free survival.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Trastuzumab botidotin more than doubled median PFS vs trastuzumab emtansine
Importance:8/10
Sentiment:
0.80
oncologybreast cancerHER2-positivePhase 3PFS
Related Companies
Read the original article
Published by Cancer Network on September 15, 2026 8:00 PM